Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-12-13
1995-09-19
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514825, 514826, 514886, 514887, C07D45302, A61K 31435
Patent
active
054515866
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates to new quinuclidine derivatives and, in particular, to 3-amino-2-aryl quinuclidines. These compounds are substance P antagonists and are useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.
U.S. Pat. No. 3,560,510 refers to certain 3-amino-2-benzhydrylquinuclidines as diuretic agents, and to the corresponding unsubstituted 3-benzylamino compounds as intermediates for preparing the same. E. J. Warawa et al., in Journal of Medicinal Chemistry, 18,587 (1975), refers to other members of the same series wherein the 3-amino moiety is either ethylamino, .beta.-phenylethylamino, .beta.-isopropylamino or 2-furfurylamino.
PCT Patent Application PCT/US 90/00116, assigned in common with the present application, refers to 3-amino piperidine derivatives and related compounds that are substance P antagonists useful in the treatment of inflammatory and central nervous system disorders.
PCT Patent Application PCT/US 88/04205, also assigned in common with the present invention, refers to cis-3-[(cyclic)methylamino]-2-[(.alpha.-substituted)arylmethyl]quinuclidin es, 3-[(cyclic)methylamine]-2-[(.alpha.-substituted)arylmethyl]quinuclidines a nd cis-3-[(cyclic)methyleneamino]-2-[(.alpha.-substituted)arylmethyl]quinucli dines that are substance P antagonists useful in the treatment of gastrointestinal disorders, central nervous system disorders,inflammatory diseases and pain.
Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt stimulatory action on smooth muscle tissue. More specifically, substance P is a pharmacologically active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in U.S. Pat. No. 4,680,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has been shown to be involved in the transmission of pain (see B. E. B. Sandberg et al., Journal of Medicinal Chemistry, 25, 1009 (1982)), and more recently in the etiology of migraine and cluster headache (P. J. Gaddsby et al., Ann. Neurol., 23, 193 (1988)), as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, and in gastrointestinal disorders such as ulcerative colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache," edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, pp. 85-95, (1987)).
In the past, some attempts have been made to provide peptide-like substances that are antagonists for substance P and other tachykinin peptides in order to more effectively treat the various disorders and diseases listed above. The peptide-like nature of such substances make them too labile from a metabolic point of view to serve as practical therapeutic agents in the treatment of disease. The non-peptide antagonists of the present invention, on the other hand, do not possess this drawback.
SUMMARY OF THE INVENTION
The present invention relates to compounds of the formula ##STR2## wherein R.sup.1 is hydrogen or (C.sub.1 -C.sub.6)alkyl; R.sup.2 is phenyl, pyridyl, thienyl or furyl, and R.sup.2 may optionally be substituted with from one to three substituents independently selected from (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, chloro, fluoro, bromo, iodo, and trifluoromethyl; R.sup.3 is phenyl, naphthyl, pyridyl, thienyl or furyl, and R.sup.3 may optionally be substituted with from one to three substituents independently selected from (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.4)alkoxy, chloro, fluoro, bromo, iodo and trifluoromethyl; and the pharmaceutically acceptable salts of such compounds.
Preferred compounds of the formula I are those wherein R.sup.2 is 2-
REFERENCES:
patent: 3560510 (1971-02-01), Warawa
patent: 5162339 (1992-11-01), Lowe
Warawa et al., J. Med. Chem., 18, 587 (1978).
Sandberg et al., J. Med. Chem., 25, 1009 (1982).
Goadsby et al., Ann. Neurol., 23, 193 (1988).
Sterling, "Quaternary and Tertiary Quinuclidines Derivatives . . . ", J. Pharm. Sci., vol. 80, No. 8, 1991 pp. 785-789.
Regoli et al., "Trends in Cluster Headache", edited by Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, pp. 85-95 (1987).
Fuller Jr. Grover F.
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
Richter Johann
LandOfFree
3-amino-2-aryl quinuclidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-amino-2-aryl quinuclidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-amino-2-aryl quinuclidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1828302